Incyte Corp. has announced two new trials that are currently recruiting ET and PV patients:
- Recruiting Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
- Recruiting Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
According to representatives from Incyte, the RELIEF trial is designed to understand better and measure how ruxolitinib treats the burden of symptoms reported by PV patients taking Hydroxyurea. Reported symptoms include tiredness, itching, muscle aches, and night sweats. Dr. Ruben Mesa recently recorded a video discussing PV and these trials in particular. Click here to watch the video.